134 completed, 39 terminated, 26 recruiting, 25 unknown. 248 Phase 2, 56 Phase 1, 20 Phase 3.
Follow Bronchiolitis: new trials by email Literature Review of Bronchiolitis trials Research Report on Bronchiolitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB) AHB-137, TVAX-008, Placebo - Chronic Hepatitis B | Phase 1 / Phase 2 | Not yet recruiting | Grand Theravac Life Sciences (Hangzhou) Co., Ltd. | 105 | 2026-10-31 | 2026-10-27 |
| Efficacy of an Anti-TSLP Monoclonal Antibody in the Management of Chronic Bronchial Disease Induced by Bronchiolitis Obliterans Syndrome in Allogeneic Hematopoietic Stem Cells Transplantation Recipients Tezepelumab - Bronchiolitis Obliterans Syndrome (BOS), HSCT | Phase 2 | Recruiting | Hopital Foch | 36 | 2026-06-24 | 2026-08-18 |
| Study of AHB-171 in Chronic Hepatitis B Participants AHB-171 Injection - Hepatitis B, Chronic (CHB) | Phase 2 | Recruiting | Ausper Biopharma Co., Ltd. | 138 | 2026-06-24 | 2026-07-21 |
| A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) INCA034176, Best available Treatment (BAT) - Chronic Graft-versus-host-disease | Phase 2 | Recruiting | Incyte Corporation | 60 | 2026-05-20 | 2026-10-09 |
| Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP Asciminib single agent - Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive | Phase 2 | Recruiting | Novartis Pharmaceuticals | 50 | 2026-04-28 | 2026-10-15 |
| Brain State-dependent PCMS in Chronic Stroke Brain state-dependent paired corticomotoneuronal stimulation (PCMS) - Stroke | Phase 1 / Phase 2 | Not yet recruiting | University of Texas at Austin | 45 | 2026-01-01 | 2024-12-06 |
| Ketamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression Ketamine hydrochloride, Minimally Enhanced Usual Care, Brief narrative intervention - Chronic Low Back Pain, Depression | Phase 2 | Recruiting | VA Office of Research and Development | 44 | 2025-12-03 | 2025-12-18 |
| A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK) Belumosudil - Chronic Graft Versus Host Disease | Phase 2 | Recruiting | Sanofi | 37 | 2025-12-02 | 2026-09-22 |
| Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias fostamatinib - Immune Mediated Anemia, Immune Mediated Thrombocytopenia | Phase 2 | Withdrawn | National Heart, Lung, and Blood Institute (NHLBI) | 2025-11-07 | 2025-11-10 | |
| A Prospective Study of Madecassoside Tablets in Sclerotic Chronic Graft-versus-Host Disease After Allo-HSCT Madecassoside Tablets, Standard Therapy - Chronic Graft-Versus-Host Disease, Graft vs Host Disease | Phase 2 | Recruiting | WeiShi | 30 | 2025-09-01 | 2026-05-26 |
| Axatilimab for Sclerotic Chronic Graft-versus-Host Disease Axatilimab, Biospecimen Collection, Questionnaire Administration - Chronic Graft Versus Host Disease | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 50 | 2025-08-06 | 2026-09-24 |
| Chronic Exogenous Ketosis in HFpEF Exogenous Ketone Drink, Placebo - Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Normal Ejection Fraction | Phase 2 | Enrolling by invitation | Duke University | 20 | 2025-07-28 | 2026-10-14 |
| Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy Gecacitinib Hydrochloride Tablets - Chronic Graft Versus Host Disease | Phase 1 / Phase 2 | Recruiting | Yujun DONG | 24 | 2025-06-30 | 2025-06-10 |
| A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD INCA034176 - Chronic Graft-versus-host-disease | Phase 1 / Phase 2 | Active not recruiting | Incyte Corporation | 32 | 2025-06-25 | 2026-08-10 |
| Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy Belumosudil - Chronic Graft Versus Host Disease | Phase 2 | Withdrawn | Kadmon, a Sanofi Company | 2025-06-16 | 2026-02-12 | |
| Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease Axatilimab, Extracorporeal Photopheresis - Chronic Graft Versus Host Disease, cGVHD | Phase 2 | Recruiting | University of Miami | 49 | 2025-05-05 | 2026-06-22 |
| Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients Dapagliflozin (DAPA), Erythropoiesis Stimulating Agent - Chronic Kidney Disease(CKD), Anemia, Kidney Disease, Chronic | Phase 2 | Recruiting | Mansoura University | 80 | 2025-04-01 | 2025-04-02 |
| Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients Belumosudil, Placebo for Belumosudil - Lung Transplant | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 234 | 2025-03-12 | 2026-08-10 |
| Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy Ruxolitinib, Prednisone - Chronic Graft-versus-host Disease (cGVHD) | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 120 | 2024-12-23 | 2026-08-05 |
| Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant Echocardiography Test, Ibrutinib - Chronic Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Terminated | Mayo Clinic | 2 | 2024-12-13 | 2026-05-22 |
Showing 20 of 248. Sign in to see all of them.
Bronchiolitis Obliterans Syndrome (205) · Graft vs Host Disease (27) · Bronchiolitis Obliterans (22) · Leukemia (18) · Leukemia, Lymphocytic, Chronic, B-Cell (12) · Pulmonary Disease, Chronic Obstructive (9) · Lymphoma, Follicular (8) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (7) · Pain (7) · Hematologic Neoplasms (6) · Hepatitis B (6) · Stroke (6) · Hepatitis C (5) · Immune System Diseases (5)
Bronchial Diseases (246) · Bronchitis (246) · Lung Diseases (246) · Respiratory Tract Diseases (246) · Lung Diseases, Obstructive (245) · Organizing Pneumonia (206) · Immune System Diseases (204) · Bronchiolitis Obliterans (200) · Graft vs Host Disease (180) · Pathological Conditions, Signs and Symptoms (78) · Pathologic Processes (54) · Infections (49) · Disease Attributes (43) · Hemic and Lymphatic Diseases (43)
Rituximab (10) · Prednisone (9) · Sirolimus (9) · belumosudil (9) · ibrutinib (9) · axatilimab (7) · montelukast (7) · Formoterol Fumarate (6) · Mycophenolic Acid (6) · ruxolitinib (6) · Azithromycin (5) · Cyclophosphamide (5) · Fluticasone (5) · KD025 (5) · Photopheresis (5)
National Cancer Institute (NCI) (8) · Novartis Pharmaceuticals (8) · Dana-Farber Cancer Institute (7) · Fred Hutchinson Cancer Center (7) · AstraZeneca (6) · Incyte Corporation (6) · M.D. Anderson Cancer Center (5) · Assistance Publique - Hôpitaux de Paris (4) · National Heart, Lung, and Blood Institute (NHLBI) (4) · Gilead Sciences (3) · H. Lee Moffitt Cancer Center and Research Institute (3) · Kadmon, a Sanofi Company (3) · Nanfang Hospital, Southern Medical University (3) · Northside Hospital, Inc. (3) · Alexion Pharmaceuticals, Inc. (2)
United States (128) · Germany (30) · Canada (29) · United Kingdom (24) · Spain (23) · China (21) · France (17) · Italy (16) · Belgium (15) · Poland (13) · Australia (11) · Russia (11) · South Korea (11) · Japan (10) · Netherlands (9)
Stephanie Lee (6) · Aldo T Iacono, MD (2) · Charles S Cox, MD (2) · Christopher G Kanakry, M.D. (2) · Esther Garcia, MD (2) · Jamie Y Hur, D.O. (2) · John Koreth, MBBS, DPhil (2) · Nicole J Gormley, M.D. (2) · Radmila Razlog, M.TechHom (2) · Scott R Solomon, MD (2)
PMID 23861248, PMID 24432712, PMID 25287629, PMID 31260802, PMID 34265047, PMID 34773261, PMID 36440464, PMID 38485149, PMID 39704205, PMID 10387937, PMID 10845940, PMID 10997973, PMID 11222360, PMID 11509929, PMID 11756187, PMID 11981005, PMID 12070007, PMID 12931119, PMID 14512314, PMID 15142114, PMID 15251978, PMID 15292060, PMID 15613541, PMID 16046530, PMID 16186597, PMID 16239908, PMID 16407509, PMID 16551963, PMID 16788100, PMID 16946302, PMID 17549053, PMID 17671231, PMID 18219306, PMID 18502835, PMID 18827155, PMID 19047234, PMID 19439742, PMID 19597425, PMID 19745067, PMID 20100768, PMID 20399493, PMID 20634158, PMID 20965785, PMID 21039672, PMID 21073773, PMID 21471175, PMID 21937568, PMID 21978929, PMID 22155140, PMID 22197578
2015 (4), P30CA015704 (4), 2017 (3), 2018 (3), 2009 (2), 2014 (2), 2019 (2), 2005 (1), 2008 (1), 2016 (1), 2025 (1), IK2CX002646-01A2 (1), IK2RX003790 (1), P01CA142106 (1), P30CA042014 (1)